stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Revenue growth
Ascendis Pharma A/S's revenue growth over the twelve months to 30 June 2026 was 126.0%, up 18.9 percentage points from fiscal 2025 (107.1%). Over the past ten years it has ranged from −66.1% (fiscal 2017) to 622.6% (fiscal 2018); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 107.1% | 70.75 |
| FY2024 | 36.3% | (399.09) |
| FY2023 | 435.4% | (50.51) |
| FY2022 | 485.9% | 470.05 |
| FY2021 | 15.9% | 62.84 |
| FY2020 | −47.0% | (66.86) |
| FY2019 | 19.9% | (602.69) |
| FY2018 | 622.6% | 688.64 |
| FY2017 | −66.1% | (22.61) |
| FY2016 | −43.5% | 8.04 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 119.9% | (51.50) |
| Mar 2026 | 171.4% | 122.06 |
| Dec 2025 | 49.3% | (243.36) |
| Sep 2025 | 292.7% | (70.13) |
| 42 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| INSM Insmed, Inc. compare | 240.0% |
| BBIO BridgeBio Pharma, Inc. compare | 167.3% |
| ASND Ascendis Pharma A/S | 126.0% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 56.2% |
| HALO Halozyme Therapeutics, Inc. compare | 45.0% |
| JAZZ Jazz Pharmaceuticals PLC compare | 13.5% |
| EXEL Exelixis, Inc. compare | 9.12% |
| BNTX BioNTech SE Sponsored ADR compare | −22.7% |
| SMMT Summit Therapeutics PLC compare | −61.0% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement